Topcon And LensAR Announce Equity Investment As Part Of Strategic Partnership
Thursday, October 06, 2011
Topcon and LensAR Announce Equity Investment as Part of Strategic Partnership
Topcon Europe Medical BV (Rotterdam, Netherlands)(“Topcon”) and LensAR Inc. (Orlando, Florida)(“LensAR”) announce that Topcon has made an equity investment in LensAR in addition to their entering into the long term strategic cooperation announced on September 16th, 2011 which included the distribution and marketing of the LensAR™ Laser System in Europe. The announcement preceding the start of ESCRS meeting in Vienna, Austria last month was well received and has resulted in several Indication of Interest deposits taken towards future delivery upon commercialization of the LensAR Laser System in Europe by Topcon.
Eric Franken, Managing Director, Topcon Europe Medical BV comments: “This is a very exciting opportunity for Topcon to demonstrate our commitment to technologies that will have a positive and significant impact on enhancing patient outcomes that are synergistic with our portfolio of products in ocular surgery, implants and diagnostics. This latest announcement shows our commitment and confidence in the LensAR Laser System to expand our offering to our partner, the ophthalmic surgeon, and help us continue to combine our quality diagnostics with the newest surgical technologies.”
Randy Frey, President & CEO LensAR Inc comments: “We are very pleased at the reception we received at the recent ESCRS by the Topcon organization as well as the entire medical community. This enthusiastic response and interest in LensAR is a strong endorsement of our decision to join forces with such a quality strategic partner. The Topcon investment underscores their confidence in LensAR and the commitment to the integration and success of this technology in their partner physician practices. Topcon is well positioned and poised to market LensAR’s superior laser system in the European market.”
About LensAR, Inc.
LensAR, Inc. is a leader in the development and commercialization of a next generation laser and advanced 3D imaging technology for refractive cataract surgery. For more information please visit www.lensar.com
The LensAR™ Laser System is cleared by the FDA for anterior capsulotomy and lens fragmentation. For other indications it is an investigational device limited by US law to investigational use only. The system has been used in more than 500 eyes outside the United States to date.
Nick Curtis, 954-889-7804
Chief Commercial Officer